NanoViricides

NNVC

Market cap $40.7M

SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received National Ethics Committee approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC). The Company is now getting ready to file a Clinical Trial Application to ACOREP, the regulatory agency in DRC.

SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a Coverage Initiating Research Report on the Company by an Independent Analyst has been published, dated as of July 6, 2026. The report rates the Company with a rating of "Outperform" and has assigned a target price of $6.00, based on the analyst's estimates.

SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral drug NV-387 towards a Phase II Clinical Trial of the NV-387 Oral Gummies formulation as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC). NanoViricides has already put together a team with a renowned Principal Investigator and with support from a well known University in the Ebola-affected region for the execution of this clinical trial after regulatory approvals.

SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted a "Rare Pediatric Disease Drug" (RPDD) Designation by the US FDA Office of Orphan Products Development (OOPD). This RPDD designation enables that a Priority Review Voucher (PRV) can be issued to the Company upon a successful Marketing Application (i.e.

SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical Trial of Monkeypox Treatment to the Democratic Republic of Congo (DRC), in preparation for enrollment of patients.

SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that its proposal to perform a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus has been approved by the Pillar Committee in Charge in the Democratic Republic of Congo (DRC). There is no approved treatment or vaccine for the new variant of the Bundibugyo Ebolavirus (BDBV) that is causing the current rapidly expanding outbreak of the Ebolavirus Disease (EVD) in DR Congo and Uganda.

SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that it has proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus to the Committee in Charge in the Democratic Republic of Congo (DRC). The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source[1], such as fruit bats.

SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential treatment options for Ebola Bundibugyo virus strain and finds that the Company's broad-spectrum antiviral drug candidate NV-387 is worthy of evaluation in this scenario. The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source[1], such as fruit bats.

NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses. The clinical-stage antiviral drug developer sold about 1.3 million shares of common stock, or pre-funded warrants in lieu of shares, along with accompanying warrants to purchase an additional roughly 1.3 million common shares.

SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced the closing of its previously announced registered direct offering (the "Offering") of 1,333,334 million shares of common stock (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 1,333,334 common shares (the "Offering"). The Offering was made to a single, fundamental institutional investor and priced at-the-market price of US$1.50 for each common share and accompanying whole warrant to purchase one common share.